Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell
September 07, 2023 22:43 ET
|
Burning Rock Biotech Limited
GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal...
Burning Rock Reports Second Quarter 2023 Financial Results
August 31, 2023 01:30 ET
|
Burning Rock Biotech Limited
GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
June 12, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas...
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
June 02, 2023 07:34 ET
|
Adaptive Biotechnologies
New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of...
Burning Rock Provides First Quarter 2023 Business Updates and Schedules Earnings Release on May 30, 2023
April 27, 2023 01:01 ET
|
Burning Rock Biotech Limited
GUANGZHOU, China, April 27, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation...
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
April 12, 2023 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
November 11, 2021 17:52 ET
|
Adaptive Biotechnologies
Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain...
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
September 30, 2021 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Barrack, Rodos & Bacine Announces Investigation of Proposed Acquisition of Memorial Resource Development Corp. (“MRD”)
June 20, 2016 12:42 ET
|
Barrack Rodos & Bacine
PHILADELPHIA, June 20, 2016 (GLOBE NEWSWIRE) -- Barrack Rodos & Bacine announces an investigation into possible breaches of fiduciary duty by members of the board of directors of Memorial...